Microbe Magazine Podcast

Lack of access to antibiotics including those with enhanced activity against multidrug-resistant organisms is a major barrier to combat antimicrobial resistance, particularly in the developing world. Furthermore, discovering and making available new antimicrobial agents against the most pressing antibiotic-resitant organisms is a challenge due to multiple barriers. The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come. We discuss the important role that GARDP is playing in the worldwide fight against antimicrobial resistance. Topics discussed: GARDP function and role in the AMR field The strategies that GARDP is implementing to make new antibiotics available to all The future of antimicrobial research and development and the role of GARDP in this process. Guests: Jennifer

So you want validated, at-home, self-collected swabs for STI testing… Here's what you need to know!  Sexually transmitted infection rates continue to climb across the US and while testing for these diseases is widely available, for the most part it requires the patient to go to a local clinic to collect and submit their sample for testing. But, is that really necessary, especially from a test accuracy perspective? Today’s guests answer that exact question. And I’m sure that many, if not all of us would agree that the ability for patients to collect samples outside of a clinical setting has numerous benefits, including what the authors refer to as pseudo-anonymity, increased comfort and ultimately increased access to testing, which would be of particular value for patients that may avoid clinical settings due to various different socioeconomic barriers.  Watch this episode: https://youtu.be/40XCHpAFvqw Guests: Dr. Breland Hockman, who is a board certified clinical chemist and the Director of Clinical Affairs

The second High-Level Meeting on Antimicrobial Resistance (AMR) took place in New York on 26 September 2024 as the principal official, health-focused event during the UN General Assembly high-level week. The intergovernmental negotiations for the declaration were co-facilitated by Malta and Barbados. A political declaration for the meeting was produced highlighting the fact that AMR will cause even more global suffering, particularly in low- and middle-income countries. In this episode we will debrief and analyze the possible impact of these meetings and consequences for the future of AMR research and antimicrobial development.  Topics discussed: The political implications of the UN declaration on AMR. Comment of the scientific and public health impact of the declaration Elaborate on future antimicrobial research and development Guests: John Rex, MD. Chief Medical Officer, F2G Ltd; Operating Partner, Advent Life Sciences Prabha Fernandes, PhD. Board Member of GARDP (Global Antibiotic Research and Developme

The American Society for Microbiology is launching a new journal, ASM Case Reports. The journal is already accepting submissions and will begin publishing in January of 2025. We discuss ASM Case Reports and what you can expect from this new journal. Watch this episode: https://youtu.be/zHdZL0PYTuE Some of the questions we will discuss include: What is the scope of ASM Case Reports? What makes a case report or case series interesting and important? Why should people publish in ASM Case Reports? Guests: Dr. Carey-Ann Burnham (twitter/

Heteroresistance is a phenomenon that has been well characterized for many years. However, we are only now starting to understand its mechanistic basis. Indeed, the manner how bacteria respond to antibiotics is complex and phenomena such as persistance, tolerance may be overlapping with heteroresistance. Furthermore, heteroresistance seems to be common in real clinical scenarios and understanding its basis is likely to open new avenues on how we deploy antibacterials in clinical practice., Today, we have experts in the field to discuss this important topic. Watch this episode at https://youtu.be/qcIcyn1bIHU. Topics discussed: The differences between heteroresistance, persistence and tolerance The mechanistic basis both in Gram-positive and Gram-negative bacteria The clinical implication and diagnosis of heteroresistance Guests: David Weiss, Ph.D. Professor of Medicine and Director Center for Antimicrobial Resistance, Emory University School Of Medicine, Atlanta. GA. William Miller, MD. Assistant Professor

Join Dr. Ben Pinsky and Dr. Greg Berry as they dissect recent news stories, including the USDA's testing for H5N1 in ground beef and a surprising bubonic plague case in Oregon. They also tackle the resurgence of measles in the U.S., the local reappearance of malaria, and a curious study on Neosporin's potential to prevent viral infections. Overview: H5N1 Influenza Virus: Dr. Ben Pinsky provides an update on recent cases of H5N1 in humans and animals, including concerns about dairy cattle infections and the potential for human transmission. Bubonic Plague: Dr. Greg Berry discusses a recent case in Oregon, its transmission through cats, and the historical context of the plague. Measles: The resurgence of measles in the U.S. is addressed, with Dr. Pinsky noting an increase in cases compared to previous years and emphasizing the importance of vaccination. Malaria: The episode covers recent cases of locally acquired malaria in the U.S. and discusses the history of malaria in America. Neosporin and Viral Infection

The pipeline of antibiotic discovery is a major necessity due to the continuous evolution of resistance to currently used antimicrobials. This pipeline faces important challenges due to the lack of investment on antimicrobial research in the private sector and an economic model that discourages investment. In the last few years, however, encouraging signs are occurring but major gaps still remain. The World Health Organization has regularly assessed the preclinical and clinical antibacterial development pipeline and the latest report is now available in the journal, lets discuss it! Watch this episode: https://youtu.be/IgqWmHDIx-0 Topics discussed: The process for review of the antibacterial pipeline. The progress and gaps in antibiotic discovery The opportunities to overcome the numerous hurdles in the early stages of the antibacterial research and development space Guest: Valeria Gigante Ph.D., Team Lead at the World Health Organization's (WHO) in the AMR Division, Geneva, Switzerland. Link: Multi-year

The European alchemists of the 12th century sought to find the philosopher’s stone, a substance that would transmute base metals, such as lead, into precious metals, such as silver and gold. Today, we discuss whether data analysis, including machine learning, can transmute base laboratory data into precious clinical tools. We will use antimicrobial susceptibility testing as a case-study for new applications of data analysis. Some of the questions we will address include: How can relatively simple data analyses be used to build upon current methods of verification of antimicrobial susceptibility testing? How do commercial systems analyze individual susceptibility results and can we improve on this analysis using new methods? Finally, what is the long-term potential for leveraging laboratory data and other clinical data to improve and support clinical decision making? And what needs to happen to realize this goal? Guests: Dr. Sanjat Kanjilal (twitter/

Antimicrobial resistance is a priority public health problem with complex roots and connotations. However, due to a lack of focus on this topic, research training programs, specifically those focused on AMR are limited. Additionally, scientific meetings that particularly highlight the science of antimicrobial resistance are scarce. We recently published a commentary that evaluates the state-of-the-art of the training programs in AMR in the US. We discuss this topic with the leading author and discussed the issue with leaders in the field. Topics discussed: The challenges that training in AMR poses and how to approach them. The current status of training programs in the USA Specific strategies that could improve the access and dissemination of AMR research  Guest: William M Shafer, PhD,  Professor, Department of Microbiology and Immunology; Director Antimicrobial Resistance and Therapeutic Discovery Training Program. Lee H. Harrison, M.D. Professor of Medicine and Epidemiology, Associate chief of epidemiolo

Rhodococcus infections are uncommon, however they can cause serious disease in certain patients. There are a number of challenges though when dealing with Rhodococcus infections, including the fact that much of what we know around their susceptibility profiles and the clinical management of infected individuals actually comes from a number case series and in some situations, from the veterinary literature.  So today, our two guests are going to tell us about their experiences with Rhodococcus over a 10-year period and bring us up-to-speed on things like:   Which species of Rhodococcus are most commonly isolated and associated with clinical disease What is the recommended approach to susceptibility testing for Rhodococcus and what sorts of susceptibility trends do we see at both the genus and species levels And also, of course, we’re going to talk about the clinical manifestations and outcomes of clinically significant Rhodococcus infections Guests: Adi S. Shah, M.B.B.S., Mayo Clinic Nancy L. Wengenack, Ph.

Phage therapy has gained a lot of traction but the challenges created by this approach have not been properly assessed at a big scale. We often read about therapy successes on isolated cases but, rarely, we read or hear about failures. AAC recently published a case series of patients who failed phage therapy. Today, we will discuss this topic with the principal investigator on the research. Topics discussed: Phage therapy as an approach for MDR bacteria. The challenges of phage therapies. Issues that can influence the success of phage therapy Guest: Saima Aslam, MBBS. Director, Solid Organ Transplant Infectious Diseases Service, Professor of Medicine, University of California, San Diego. Article: Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases https://journals.asm.org/doi/10.1128/aac.01728-23 Questions Answered: How are we doing with phage therapy at this point? What are the challenges to deploy phage therapy in clinical settings? The 5

The protozoan Lophomonas has been reported to be a pathogen of humans in a large number of case reports and case series. Most of these case reports describe infections of the respiratory tract. Editors in Conversation is joined by two experts to discuss this possible parasite. Some of the questions addressed include: What are the characteristics of the species in the genus Lophomonas? What are the laboratory and morphological data that suggest that Lophomonas species cause human infections? What are the purported clinical manifestations of Lophomonas? Finally, is Lophomonas truly a pathogen of humans? Guests: Dr. Abhishek Mewara - Additional Professor in the Department of Medical Parasitology at the Postgraduate Institute of Medical Education and Research in Chandigarh, India. Dr. Bobbi Pritt - Chair of the Division of Clinical Microbiology and Professor of Laboratory Medicine and Pathology at May Clinic. Related article: “Lophomonas as a respiratory pathogen—jumping the gun,” by Abhishek Mewara, Gillian

Tuberculosis is one of the most deadly infectious diseases that still causes significant burden of disease, particularly in the developing world.  The emergence of resistance to first line agents severely limits the therapeutic options and threaten the ability to control dissemination of this disease. Fortunately, new drugs and regimens are now emerging as important alternatives against these organisms.  Today, we will discuss this topic with outstanding experts in the field. Welcome to the editors in conversation. Topics discussed: The burden of multidrug-resistant TB. New drugs and regimens for MDR TB. The current and future pipeline for TB Guests: Kelly Dooley, MD Ph.D.  Professor and Addison B. Scoville, Jr., Chair in Medicine, Director, Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center. Past Editor of AAC Sean Wasserman, MD Ph.D, Reader in Infectious Diseases at St Georges University of London and Associate Professor in the Division of Infectious Diseases an

A new generation of B-lactamase inhibitors is likely to reach the market in the upcoming year. These broad-spectrum inhibitors exhibit activity against the most feared class B metallo-B-lactamases maintaining the inhibition of other enzymes. Recently AAC has published three papers that describe the mechanistic bases of taniborbactam resistance among metallo-enzymes. This knowledge is crucial to understand the limitation of these compounds in clinical practice. Today, we will discuss this topic with some of the authors of the mentioned papers. Welcome to the editors in conversation. Topics discussed: The activity and chemical basis of new generation B-lactamase inhibitors with activity against metallo-B-lactamases. Taniborbactam as an example of novel B-lactam, B-lactam inhibitors Mechanisms of resistance to taniborbactam and other inhibitors Guest: Robert Bonomo, MD.  Director of the VA CARES Center and Distinguished Professor at Case Western Reserve University (CWRU) School of Medicine. Past Editor of AAC

We managed to make it through 2023 without a major epidemic or pandemic, and as we get into the holiday spirit and look forward to the new year, some of us took a look back and picked out one of our favorite JCM paper published in 2023, which I will tell you, was no easy task as there were many of good ones to choose from! And personally, after looking through all the issues over the last year, it never ceases to amaze me the variety of topics that we publish on in JCM – including unique things like the evaluation of a molecular assay for diagnosis of Buruli ulcers, to development of an EIA for detection of Taenia coproantigen, and then of course we have the more bread and butter things like evaluation of new assays for detection of TB resistance, to multiple studies this year on women’s health diagnostics, and evaluation of new molecular assays for congenital CMV detection, and then I’m also told that there were some awesome AST-focused papers too, which is all just great. The four of us JCM editors have se

Gonorrhea remains one of the more common sexually transmitted infections. In North America, the number of reported cases has generally risen for over ten years, with interruptions in the early days of the COVID-19 pandemic, followed by returns to rising rates of infection. Under the selective pressure of antimicrobial treatment, antimicrobial resistance has risen, which has led to limited options for treatment Today, we will be discussing antimicrobial resistance in N. gonorrhoeae, including these questions:     •    How accurate is gradient diffusion susceptibility testing when compared to agar-dilution results?     •    Should we use analysis of whole genome sequencing results or agar dilution phenotypic results as the gold-standard for antibiotic susceptibility testing of N. gonorrhoeae?     •    What is the utility of beta-lactamase testing for predicting penicillin susceptibility results in N. gonorrhoeae?   Guests: Dr. Tanis Dingle, Clinical Microbiologist at Alberta Precision Laboratories and a Clini

In the last few years we have witnessed the rise of very resistant fungal species some of them likely influenced by environmental conditions and climate change. Fortunately, there has been a bit of an explosion in the development of new antifungals and the pipeline has been strengthened in the last decade. We will have the ability to have new molecules with distinct and novel mechanisms of action in the near future that may contribute to combat recalcitrant fungal infections. Topics discussed: The overall threat of fungal resistance. The antifungal pipeline in the last few years. New promising antifungals Guests: Andreas Groll, MD PhD, Professor of Pediatrics, Head of the Infectious Disease Research Programme and Deputy Director of the Department of Haematology/Oncology at the University Children's Hospital in Münster, Germany. Editor AAC This episode of Editors in Conversation is brought to you by the Antimicrobial Agents and Chemotherapy Journal and hosted by AAC Editor in Chief, Cesar Arias.  AAC is av

Despite the many advances in diagnostic testing for infectious diseases, detection of Coccidoides infections continues to rely on serologic assessment for anti-fungal antibodies, and what is perhaps more astonishing is that the serologic methods we use today, such as complement fixation and immunodiffusion, were first developed about a century ago. These assays are technically challenging to maintain and perform, and as a result few labs offer this testing, and even if performed on-site, testing can take up to 3 days complete, so there is definitely room for improvement. So today, we are talking about a study that aimed to modernize and improve our current options and diagnostic approach for Valley Fever, using a simpler and definitely faster lateral flow immunoassay. And as an added bonus, the study was not homo sapien-centric. Guests: Dr. Francisca Grill, Chief Scientific Officer at Cactus Bio Dr. Tom Grys, Associate Professor of Laboratory Medicine and Pathology, and co-Director of the Clinical Microbiol

Climate change is possibly the major threat that planet earth is experiencing in this century with potential catastrophic consequences. As the planet warms, the change in weather patterns is affecting the microbial ecology in such a manner that humans are facing new health threats including emerging diseases and facing species of organisms that are more likely to survive these new climatic conditions and resist clinically useful antimicrobials. Topics discussed: The global threat of global warming. Climate change and change sin microbial ecology. The consequences of climate change and emergence of new infectious diseases and antimicrobial resistance patterns. Guests: Arturo Casadeval MD, Bloomberg Distinguished Professor, Alfred & Jill Sommer Professor and Chair Department of Molecular Microbiology & Immunology, Johns Hopkins Bloomberg School of Public Health. Editor in Chief of mBio, Member of the National Academy of Sciences

Fungi that are resistant to antifungal drugs have been very much in the news and even the subject of the hugely popular television program, The Last of Us. We talk with two experts in mycology and fungal susceptibility testing about the recent descriptions of terbinafine-resistant dermatophytes in the United States. Some of the questions we will address include:  • What are the manifestations of infections caused by terbinafine-resistant dermatophytes?  • What species, including novel species, of dermatophytes are more commonly resistant to terbinafine?  • How common is terbinafine resistance in dermatophytes in the U.S.? Guests: - Dr. Shawn Lockhart - Senior Advisor at the Centers for Disease Control - Dr. Nathan Wiederhold - Director of the Fungus Testing Laboratory and a Professor at UT Health San Antonio. This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. Editors in conversation is supported b